Zobrazeno 1 - 10
of 212
pro vyhledávání: '"Yuti Chernajovsky"'
Autor:
Ilse Zündorf
Publikováno v:
Pharmazie in unserer Zeit. 37:340-340
Autor:
Osvaldo L. Podhajcer, Yuti Chernajovsky, David Gould, Cecilia Carbone, Eduardo G. Cafferata, Diego L. Viale, Patricia Blanco, María V. Lopez
Supplementary Data from Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::032059c5669363577f4c0507552f5393
https://doi.org/10.1158/1535-7163.22485266.v1
https://doi.org/10.1158/1535-7163.22485266.v1
Autor:
Osvaldo L. Podhajcer, Yuti Chernajovsky, David Gould, Cecilia Carbone, Eduardo G. Cafferata, Diego L. Viale, Patricia Blanco, María V. Lopez
The successful use of transcriptional targeting for cancer therapy depends on the activity of a given promoter inside the malignant cell. Because solid human tumors evolve as a “cross-talk” between the different cell types within the tumor, we hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b3bef28bfe5f3e0ccf34f2b22f5a20c
https://doi.org/10.1158/1535-7163.c.6531863
https://doi.org/10.1158/1535-7163.c.6531863
Autor:
Lorna Chernajovsky, Christopher D. Buckley, Luke A. J. O'Neill, Paul P. Tak, Louise K. Modis, Rachel Connor, Elizabeth A. Waterman, Yuti Chernajovsky, David Coutts, Doug Brown
Publikováno v:
Nature Immunology. 22:1344-1348
If new treatments for immune-mediated inflammatory diseases (IMIDs) are to emerge, then a radical new approach that moves the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms i
Autor:
Ilaria Cervellini, Alexander Annenkov, Thomas Brenton, Yuti Chernajovsky, Pietro Ghezzi, Manuela Mengozzi
Publikováno v:
Molecular Medicine, Vol 19, Iss 1, Pp 223-229 (2013)
Abstract Erythropoietin (EPO) has protective effects in neurodegenerative and neuroinflammatory diseases, including in animal models of multiple sclerosis, where EPO decreases disease severity. EPO also promotes neurogenesis and is protective in mode
Externí odkaz:
https://doaj.org/article/c7dcda4a3fa74e23bde0e4b6059b0fd9
Autor:
Maria E. Riveiro, David Gould, Keyvan Rezai, Giulia Taraboletti, Yuti Chernajovsky, Marina Meroni, Massimo Russo, Patrizia Borsotti, Roberta Frapolli, Christopher Schultz
Publikováno v:
Cancer Research. 81:916-916
Background. Recombinant IL-2 (rIL-2; aldesleukin) has consistently shown single agent responses and survival benefits in metastatic melanoma and renal cell carcinoma. However, severe toxic side effects associated with high doses, as well as the poor
Autor:
M Verónica Lopez, Diego L Viale, Eduardo G A Cafferata, Alicia I Bravo, Cecilia Carbone, David Gould, Yuti Chernajovsky, Osvaldo L Podhajcer
Publikováno v:
PLoS ONE, Vol 4, Iss 4, p e5119 (2009)
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-asso
Externí odkaz:
https://doaj.org/article/d79f19cd56fc43ba8289f110672aec01
Autor:
Zündorf, Ilse
Publikováno v:
Pharmazie in unserer Zeit; July 2008, Vol. 37 Issue: 4 p340-340, 1p
Autor:
Andrew Nesbitt, R Cartwright, Hill Gaston, Helen Lockstone, Pierre Quartier, Karim Raza, Costantino Pitzalis, R Preiss, Nikunjana A. Patel, Natasha Sahgal, Louisa E. Jeffery, Tracy Hussell, Jane C. Goodall, Louise McNeill, Marc Feldmann, Marco Gattorno, Andrew Filer, Yuti Chernajovsky, Kieron S. Leslie, Lou Ellis, Jim Middleton, Saba Alzabin, Ayman Askari, Jennifer A. Smith, Eric Hachulla, J Hoyer, David M. Sansom, Helen J. Lachmann, Gianluca Fossati, Mark Peakman, Isabelle Koné-Paut, Philip N. Hawkins, Gayatri Mittal, J. B. Kuemmerle-Deschner, Katrina Blazek, Paolo Pozzilli, Michele Bombardi, A Widmer, Timothy Smallie, Thomas Krausgruber, Irina A. Udalova, Ahmet Gül, Rizgar A. Mageed, Elisa Astorri, Catherine Whittall
Background: Activities of the anti-TNFs, certolizumab pegol (CZP), etanercept (ETA), infliximab (IFX) and adalimumab (ADA), have been compared in a range of in vitro assays. CZP is the only licensed PEGylated Fab' anti-TNF; ETA is a fusion protein wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef740867bf37a3acfc7df12af47c033
http://doc.rero.ch/record/300594/files/ker035.pdf
http://doc.rero.ch/record/300594/files/ker035.pdf
Autor:
Cma Schultz, Yuti Chernajovsky
Publikováno v:
Poster Presentations.
Background Rheumatoid Arthritis (RA) is a debilitating inflammatory disease of the joints afflicting around 1% of Western populations. Some of the best treatments are anti-TNF agents, but these only achieve remission in 60% of patients and cause dele